Azithromycin and the risk of cardiovascular death [3]

New England Journal of Medicine

Volumn 367, Issue 8, 2012, Pages 772-775

  Knirsch, Charles A ^a   Chandra, Richa ^a  

^a PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZITHROMYCIN; PLACEBO;

CARDIOVASCULAR RISK; CORONARY ARTERY DISEASE; HEART DEATH; HUMAN; LETTER; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; RISK REDUCTION;

EID: 84865281608     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMc1207269     Document Type: Letter

References (6)

1. Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-90.
2. Grayston JT, Kronmal RA, Jackson LA, et al. Azithromycin for the secondary prevention of coronary events. N Engl J Med 2005;352:1637-45.
3. O'Connor CM, Dunne MW, Pfeffer MA, et al. Azithromycin for the secondary prevention of coronary heart disease events: the WIZARD Study: a randomized controlled trial. JAMA 2003; 290:1459-66.
4. Fossa AA, Wisialowski T, Duncan NJ, Deng S, Dunne M. Azithromycin/ chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig. Am J Trop Med Hyg 2007;77:929-38.
5. Thomsen MB, Beekman JDM, Attevelt NJM, et al. No proarrhythmic properties of the antibiotics moxifloxacin or azithromycin in anesthetized dogs with chronic-AV block. Br J Pharmacol 2006;149:1039-48.
6. Zithromax. New York: Pfizer (package insert) (http://labeling.pfizer.com/ ShowLabeling.aspx?id=513).